EP3790972A1 — Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
Assigned to Regulus Therapeutics Inc · Expires 2021-03-17 · 5y expired
What this patent protects
Described herein are compositions and methods for the inhibition of miR-l22 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-l22 activity and comprise moieties that facilitate delivery to the liver. The compositions may be admin…
USPTO Abstract
Described herein are compositions and methods for the inhibition of miR-l22 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-l22 activity and comprise moieties that facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.